Allergen (NYSE:AGN) Gets Botox Boost

Allergen (NYSE:AGN) is one of Susquehanna's top picks for 2011, based on what they see as an increase in Botox sales.

For 2011 they see sales reaching $15 million; for 2012 Botox sales are expected to climb to $65 million; and for 2013-14, they're estimated to come in at $100 million.

EPS estimates for Allergen in 2012 and 2013 were raised by $0.02, and for 2014 by $0.04. Over the next few years Susquehanna believes Allergen's EPS will grow by close to 15 percent.

Allergen closed Wednesday at $70.72, losing $1.36, or 1.89 percent.